Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 5/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368619 | 0.84 | GPR119 (0.43) | KDM1AMGLLGPR119 | |
| SCHEMBL10171868 | 0.82 | KDM1A (0.33) | KDM1AMGLLHSD11B1AOC3 | |
| SCHEMBL10171856 | 0.76 | L3MBTL1 (0.34) | KDM1AMGLLHSD11B1GPR119ALDH1A1 | |
| SCHEMBL10140492 | 0.69 | GPR119 (0.41) | MGLLGPR119 | |
| SCHEMBL10171863 | 0.66 | KDM1A (0.35) | KDM1A | |
| SCHEMBL357664 | 0.64 | GPR119 (0.39) | MGLLGPR119L3MBTL1 | |
| SCHEMBL357663 | 0.64 | GPR119 (0.39) | MGLLGPR119L3MBTL1 | |
| SCHEMBL15406926 | 0.63 | PRKCG (0.49) | KDM1AGPR119 | |
| SCHEMBL7888733 | 0.62 | GPR119 (0.47) | GPR119HPGD | |
| SCHEMBL23579939 | 0.61 | SMN1; SMN2 (0.56) | ALDH1A1HPGDALOX15HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | KDM1A 2838/4885MGLL 4394/4885HSD11B1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.